The NLRP3 inflammasome in progressive multiple sclerosis

Atsushi Kadowaki; Francisco J Quintana

doi:10.1093/brain/awaa135

journal article May 01, 2020

The NLRP3 inflammasome in progressive multiple sclerosis

Atsushi Kadowaki Francisco J Quintana

Brain Vol. 143 No. 5 pp. 1286-1288 · Oxford University Press (OUP)

View at Publisher Save 10.1093/brain/awaa135

Abstract

This scientific commentary refers to ‘NLRP3 inflammasome as prognostic factor and therapeutic target in primary progressive multiple sclerosis patients’, by Malhotra et al. (doi:10.1093/brain/awaa084).

Topics

No keywords indexed for this article. Browse by subject →

References

13

[1]

Baecher-Allan "Multiple sclerosis: mechanisms and Immunotherapy" Neuron (2018) 10.1016/j.neuron.2018.01.021

[2]

Barclay "Inflammasome activation in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE)" Brain Pathol (2017) 10.1111/bpa.12477

[3]

Beynon "Activated human CD4+CD45RO+ memory T-cells indirectly inhibit NLRP3 inflammasome activation through downregulation of P2X7R signalling" PLoS One (2012) 10.1371/journal.pone.0039576

[4]

Chao "Metabolic control of astrocyte pathogenic activity via cPLA2-MAVS" Cell (2019) 10.1016/j.cell.2019.11.016

[5]

Faissner "Progressive multiple sclerosis: from pathophysiology to therapeutic strategies" Nat Rev Drug Discov (2019) 10.1038/s41573-019-0035-2

[6]

Inflammasomes: mechanism of action, role in disease, and therapeutics

Haitao Guo, Justin B Callaway, Jenny P-Y Ting

Nature Medicine 2015 10.1038/nm.3893

[7]

Interleukin-1 Alters Glutamate Transmission at Purkinje Cell Synapses in a Mouse Model of Multiple Sclerosis

G. Mandolesi, A. Musella, A. Gentile et al.

The Journal of Neuroscience 2013 10.1523/jneurosci.5369-12.2013

[8]

Mascanfroni "IL-27 acts on DCs to suppress the T cell response and autoimmunity by inducing expression of the immunoregulatory molecule CD39" Nat Immunol (2013) 10.1038/ni.2695

[9]

Miller "Primary-progressive multiple sclerosis" Lancet Neurol (2007) 10.1016/s1474-4422(07)70243-0

[10]

Montalban "Ocrelizumab versus placebo in primary progressive multiple sclerosis" N Engl J Med (2017) 10.1056/nejmoa1606468

[11]

The NLRP3 inflammasome: molecular activation and regulation to therapeutics

Karen V. Swanson, Meng Deng, Jenny P.-Y. Ting

Nature Reviews Immunology 2019 10.1038/s41577-019-0165-0

[12]

Verma "The Q705K polymorphism in NLRP3 is a gain-of-function alteration leading to excessive interleukin-1beta and IL-18 production" PLoS One (2012) 10.1371/journal.pone.0034977

[13]

MAFG-driven astrocytes promote CNS inflammation

Michael A. Wheeler, Iain C. Clark, Emily C. Tjon et al.

Nature 2020 10.1038/s41586-020-1999-0

Metrics

17

Citations

13

References

Details

Published: May 01, 2020
Vol/Issue: 143(5)
Pages: 1286-1288
License: View

Authors

A

Atsushi Kadowaki

Ann Romney Center for Neurologic Diseases, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA

F

Francisco J Quintana

Ann Romney Center for Neurologic Diseases, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA

Funding

National Institutes of Health Award: RG4111A1

National Multiple Sclerosis Society

International Progressive MS Alliance

Work in the Quintana laboratory Award: NS102807

Cite This Article

Atsushi Kadowaki, Francisco J Quintana (2020). The NLRP3 inflammasome in progressive multiple sclerosis. Brain, 143(5), 1286-1288. https://doi.org/10.1093/brain/awaa135

The NLRP3 inflammasome in progressive multiple sclerosis

You May Also Like